CNTX insider transaction filings
Context Therapeutics Inc. — 35 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-26. Screen CNTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Kantoff Philip W. — Director | 1 | — | — | 1 |
| Pasternak Andy — Director | 1 | — | — | 1 |
| Smith Karen L. — Director | 1 | — | — | 1 |
| Stacey Jennifer Evans — Director | 1 | — | — | 1 |
| Walker Luke Nathaniel — Director | 1 | — | — | 1 |
| West Linda — Director | 1 | — | — | 1 |
Recent Form 4 filings — Context Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Kantoff Philip W. — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | West Linda — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Pasternak Andy — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Walker Luke Nathaniel — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Smith Karen L. — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Stacey Jennifer Evans — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Levit Alex C. — Chief Legal Officer, Corp. Sec | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Minai-Azary Jennifer Lynn — Chief Financial Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Chagin Karen Deborah — Chief Medical Officer | Grant/award (A): 290,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Lehr Martin A. — Chief Executive Officer, Director | Grant/award (A): 815,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Kantoff Philip W. — Director | Grant/award (A): 123,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | West Linda — Director | Grant/award (A): 123,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Pasternak Andy — Director | Grant/award (A): 138,900 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Walker Luke Nathaniel — Director | Grant/award (A): 123,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Smith Karen L. — Director | Grant/award (A): 123,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Stacey Jennifer Evans — Director | Grant/award (A): 123,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Lehr Martin A. — Chief Executive Officer, Director | Purchase (P): 100,000 @ $0.70 | EDGAR |
| 2025-06-10 | 4 | Levit Alex C. — Chief Legal Officer, Corp. Sec | Purchase (P): 20,000 @ $0.58 | EDGAR |
| 2025-06-10 | 4 | Minai-Azary Jennifer Lynn — Chief Financial Officer | Purchase (P): 40,010 @ $0.64 | EDGAR |
| 2025-06-09 | 4 | Chagin Karen Deborah — Chief Medical Officer | Grant/award (A): 153,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Minai-Azary Jennifer Lynn — Chief Financial Officer | Grant/award (A): 371,800 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Levit Alex C. — Chief Legal Officer, Corp. Sec | Grant/award (A): 349,900 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Dansky Ullmann Claudio — Chief Medical Officer | Grant/award (A): 174,960 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Lehr Martin A. — Chief Executive Officer, Director | Grant/award (A): 802,700 (derivative) @ $0 | EDGAR |
| 2025-01-14 | 4 | Pasternak Andy — Director | Grant/award (A): 20,685 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Walker Luke Nathaniel — Director | Grant/award (A): 19,315 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Smith Karen L. — Director | Grant/award (A): 19,315 (derivative) @ $0 | EDGAR |
| 2024-08-01 | 4 | Dansky Ullmann Claudio — Chief Medical Officer | Grant/award (A): 202,170 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Kantoff Philip W. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | West Linda — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Stacey Jennifer Evans — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | BERMAN RICHARD J — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | Minai-Azary Jennifer Lynn — Chief Financial Officer | Grant/award (A): 160,115 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | Levit Alex C. — Chief Legal Officer, Corp. Sec | Grant/award (A): 153,515 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | Lehr Martin A. — Chief Executive Officer, Director | Grant/award (A): 291,402 (derivative) @ $0 | EDGAR |
Recent 8-K events — Context Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-26 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-13 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CNTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →